Sionna Therapeutics (NASDAQ:SION) Sets New 12-Month High – What’s Next?

Sionna Therapeutics, Inc. (NASDAQ:SION)’s stock price reached a new 52-week high on Monday . The company traded as high as $45.00 and last traded at $44.21, with a volume of 5187 shares traded. The stock had previously closed at $43.70.

Wall Street Analysts Forecast Growth

SION has been the subject of several recent analyst reports. Raymond James Financial reiterated a “strong-buy” rating on shares of Sionna Therapeutics in a research note on Wednesday, November 5th. Royal Bank Of Canada reiterated an “underperform” rating and set a $24.00 price target on shares of Sionna Therapeutics in a research report on Monday, December 1st. Jones Trading started coverage on Sionna Therapeutics in a research note on Monday, September 8th. They set a “buy” rating and a $46.00 price target on the stock. BTIG Research assumed coverage on Sionna Therapeutics in a research note on Wednesday, November 19th. They issued a “buy” rating and a $50.00 price objective for the company. Finally, Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Sionna Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $43.14.

Sionna Therapeutics Trading Down 1.5%

The business has a 50 day moving average of $40.05 and a 200-day moving average of $28.35. The stock has a market cap of $1.92 billion and a PE ratio of -8.84.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

Insider Transactions at Sionna Therapeutics

In other Sionna Therapeutics news, CEO Michael Cloonan sold 99,800 shares of the company’s stock in a transaction dated Tuesday, October 21st. The shares were sold at an average price of $36.26, for a total value of $3,618,748.00. Following the transaction, the chief executive officer directly owned 547,343 shares in the company, valued at approximately $19,846,657.18. This represents a 15.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ra Capital Management, L.P. sold 311,000 shares of Sionna Therapeutics stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $39.50, for a total transaction of $12,284,500.00. Following the sale, the director owned 219,867 shares of the company’s stock, valued at approximately $8,684,746.50. This trade represents a 58.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,517,486 shares of company stock worth $55,761,982 in the last ninety days. Company insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SION. Russell Investments Group Ltd. acquired a new stake in shares of Sionna Therapeutics during the third quarter worth $30,000. BNP Paribas Financial Markets purchased a new position in Sionna Therapeutics during the second quarter worth about $31,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Sionna Therapeutics in the 2nd quarter worth about $45,000. Virtus Investment Advisers LLC purchased a new stake in Sionna Therapeutics in the 2nd quarter valued at about $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Sionna Therapeutics during the 2nd quarter valued at about $117,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.